BioSpace News Archive

Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency granted a positive opinion for the use of Veklury® in COVID-19 patients with severe renal impairment, including those on dialysis.

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that, on May 25, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 17,800 shares of the Company’s common stock to a newly hired employee.

Castle Biosciences, Inc. announced that its three posters at the recent DDW Annual Meeting were honored as “Posters of Distinction” by the AGA Institute Council, ranking among the top 10% of the more than 3,100 abstracts showcased during the meeting.

Positive high-level results from the DUO-E Phase III trial showed IMFINZI® in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer.

ProfoundBio announced that dosing in the Phase 1/2 first-in-human trial of PRO1160 has initiated in the US, and the company received approval from National Medical Products Administration to initiate the PRO1160 trial in China.

Guardant Health, Inc., a leading precision oncology company, announced the company will be participating in the following investor conferences.

Takeda announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of the American Society of Clinical Oncology being held June 2-6, 2023, in Chicago, Ill.

Invitae, a leading medical genetics company, announced nine studies to be presented at the 2023 American Society of Clinical Oncology Annual Meeting held in Chicago from June 2-6, 2023.

Ferring Pharmaceuticals announced that its clinical development partner, Seikagaku Corporation, achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation.